Litcius/Paper detail

LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

Toni K. Choueiri, Tom Powles, Laurence Albigès, M. Burotto, C. Szczylik, B. Zurawski, E. Yanez Riuz, Marco Maruzzo, Alberto Suárez Zaizar, Luis Fein, Fabio A. Schutz, Daniel Yick Chin Heng, F. Wang, Fabio Mataveli, Yih‐Leong Chang, Maximiliano van Kooten Losio, C. Suárez Rodríguez, Robert J. Motzer

2022Annals of Oncology20 citationsDOI

Topics & Concepts

MedicineClinical endpointIpilimumabInternal medicineNivolumabPopulationCabozantinibPlaceboRandomized controlled trialProgression-free survivalIntention-to-treat analysisOncologyPhases of clinical researchGastroenterologyUrologyRenal cell carcinomaCancerClinical trialChemotherapyImmunotherapyPathologyEnvironmental healthAlternative medicinePancreatic and Hepatic Oncology ResearchPhagocytosis and Immune RegulationRenal cell carcinoma treatment
LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) | Litcius